Overall, our data suggests the potential for using gene and/or protein expression levels of LRRK2, HMOX1, TLR2, TLR8, RELA, ATG7, and GABARAPL2 to follow therapeutic response with sargramostim during progression of PD. This evidence concerns the gene TLR2 and Parkinson disease.